Recent advances in cytokines in cutaneous and systemic lupus erythematosus

J Dermatol. 2011 Sep;38(9):839-49. doi: 10.1111/j.1346-8138.2011.01237.x. Epub 2011 Jul 18.

Abstract

Lupus erythematosus (LE) includes a broad spectrum of diseases from a cutaneous-limited type to a systemic type. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease which affects multiple organs. Cutaneous lupus erythematosus (CLE) includes skin symptoms seen in SLE and cutaneous-limited LE. Although immune abnormalities, as well as heritable, hormonal and environmental factors, are involved in the pathology of LE, the actual pathogenesis is still unclear. Recently, the involvement of various cytokines has been shown in the pathogenesis of LE. Moreover, some trials with biological agents targeted specific cytokines are also ongoing for SLE. In this article, we review the contributions of major cytokines such as interferon, tumor necrosis factor-α and interleukin-18 to LE, especially SLE and CLE.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cytokines / metabolism*
  • Humans
  • Interferon-alpha / metabolism
  • Interferon-gamma / metabolism
  • Interleukin-10 / metabolism
  • Interleukin-17 / metabolism
  • Interleukin-18 / metabolism
  • Interleukin-6 / metabolism
  • Lupus Erythematosus, Cutaneous / etiology
  • Lupus Erythematosus, Cutaneous / immunology*
  • Lupus Erythematosus, Cutaneous / pathology
  • Lupus Erythematosus, Systemic / etiology
  • Lupus Erythematosus, Systemic / immunology*
  • Mice
  • Models, Immunological
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cytokines
  • Interferon-alpha
  • Interleukin-17
  • Interleukin-18
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Interferon-gamma